BIOMAT Database Logo BIOMAT Database Logo

Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors. 2024

Ridong Li, and Lidong Gong, and Jiawei Sun, and Zichao Liang, and Jianan He, and Junjie Huang, and Xianling Ning, and Huajie Song, and Runtao Li, and Qiang Zhang, and Zhiqiang Lin, and Yuxin Yin
Institute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, PR China. Electronic address: lrd@bjmu.edu.cn.

Two series of 2,4-diarylaminopyrimidine derivatives containing sulfonamide moiety were designed and synthesized for screening as inhibitors of focal adhesion kinase (FAK). Most compounds significantly inhibited the enzymatic activities of FAK, and the best compound was 7b (IC50 = 0.27 nM). A majority of aminoethyl sulfonamide derivatives could effectively inhibit the proliferation of human cancer cell lines (HCT116, A549, MDA-MB-231 and Hela) expressing high levels of FAK. Particularly, compounds 7b, 7c, and 7o exhibited more significant efficacy against all of four cancer cell lines within concentrations of 1.5 μM. Furthermore, these three compounds displayed higher selectivity of cancer cells over normal cells (SI value > 14), compared to the positive control TAE226 (SI value = 1.63). Interestingly, introduction of dithiocarbamate moiety to the aminoethyl sulfonamide derivatives can indeed improve the antiproliferative activities against A549 cells. Especially, compound 8d demonstrated most significant cytotoxicity activity against A549 cells with an IC50 value of 0.08 μM, which is 20-fold superior to parent compound 7k. Additionally, compound 7b, which display the best anti-FAK potency, can inhibit the clone formation and migration of HCT-116 cells, and cause cell cycle arrest at G2/M phase, inducing apoptosis by promoting ROS production. Overall, these results suggest that 7b is a valuable FAK inhibitor that deserves further optimization to improve its druggability.

UI MeSH Term Description Entries

Related Publications

Ridong Li, and Lidong Gong, and Jiawei Sun, and Zichao Liang, and Jianan He, and Junjie Huang, and Xianling Ning, and Huajie Song, and Runtao Li, and Qiang Zhang, and Zhiqiang Lin, and Yuxin Yin
Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
September 2019, European journal of medicinal chemistry,
Ridong Li, and Lidong Gong, and Jiawei Sun, and Zichao Liang, and Jianan He, and Junjie Huang, and Xianling Ning, and Huajie Song, and Runtao Li, and Qiang Zhang, and Zhiqiang Lin, and Yuxin Yin
Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors.
January 2018, Computational and structural biotechnology journal,
Ridong Li, and Lidong Gong, and Jiawei Sun, and Zichao Liang, and Jianan He, and Junjie Huang, and Xianling Ning, and Huajie Song, and Runtao Li, and Qiang Zhang, and Zhiqiang Lin, and Yuxin Yin
Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors.
June 2017, European journal of medicinal chemistry,
Ridong Li, and Lidong Gong, and Jiawei Sun, and Zichao Liang, and Jianan He, and Junjie Huang, and Xianling Ning, and Huajie Song, and Runtao Li, and Qiang Zhang, and Zhiqiang Lin, and Yuxin Yin
Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
December 2017, European journal of medicinal chemistry,
Ridong Li, and Lidong Gong, and Jiawei Sun, and Zichao Liang, and Jianan He, and Junjie Huang, and Xianling Ning, and Huajie Song, and Runtao Li, and Qiang Zhang, and Zhiqiang Lin, and Yuxin Yin
Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
July 2018, Chemical biology & drug design,
Ridong Li, and Lidong Gong, and Jiawei Sun, and Zichao Liang, and Jianan He, and Junjie Huang, and Xianling Ning, and Huajie Song, and Runtao Li, and Qiang Zhang, and Zhiqiang Lin, and Yuxin Yin
Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors.
September 2019, European journal of medicinal chemistry,
Ridong Li, and Lidong Gong, and Jiawei Sun, and Zichao Liang, and Jianan He, and Junjie Huang, and Xianling Ning, and Huajie Song, and Runtao Li, and Qiang Zhang, and Zhiqiang Lin, and Yuxin Yin
Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
May 2018, European journal of medicinal chemistry,
Ridong Li, and Lidong Gong, and Jiawei Sun, and Zichao Liang, and Jianan He, and Junjie Huang, and Xianling Ning, and Huajie Song, and Runtao Li, and Qiang Zhang, and Zhiqiang Lin, and Yuxin Yin
Novel Thiourea Derivatives Bearing Sulfonamide Moiety as Anticancer Agents Through COX-2 Inhibition.
January 2017, Anti-cancer agents in medicinal chemistry,
Ridong Li, and Lidong Gong, and Jiawei Sun, and Zichao Liang, and Jianan He, and Junjie Huang, and Xianling Ning, and Huajie Song, and Runtao Li, and Qiang Zhang, and Zhiqiang Lin, and Yuxin Yin
Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment of pancreatic cancer.
November 2022, European journal of medicinal chemistry,
Ridong Li, and Lidong Gong, and Jiawei Sun, and Zichao Liang, and Jianan He, and Junjie Huang, and Xianling Ning, and Huajie Song, and Runtao Li, and Qiang Zhang, and Zhiqiang Lin, and Yuxin Yin
Discovery of novel PRMT5 inhibitors bearing a methylpiperazinyl moiety.
July 2022, Future medicinal chemistry,
Copied contents to your clipboard!